{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"65.8","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"56.1","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"65.8","value":"0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"56.1","value":"0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"65.8","value":"0"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"43.4","value":"0"},{"groupId":"OG006","lowerLimit":"0.0","upperLimit":"39.0","value":"0"},{"groupId":"OG007","lowerLimit":"0.0","upperLimit":"39.0","value":"0"},{"groupId":"OG008","lowerLimit":"0.0","upperLimit":"49.0","value":"0"},{"groupId":"OG009","lowerLimit":"15.0","upperLimit":"85.0","value":"50.0"},{"groupId":"OG010","lowerLimit":"4.6","upperLimit":"69.9","value":"25.0"},{"groupId":"OG011","lowerLimit":"18.8","upperLimit":"81.2","value":"50.0"},{"groupId":"OG012","lowerLimit":"18.8","upperLimit":"81.2","value":"50.0"},{"groupId":"OG013","lowerLimit":"2.6","upperLimit":"51.3","value":"14.3"},{"groupId":"OG014","lowerLimit":"23.2","upperLimit":"70.9","value":"46.2"},{"groupId":"OG015","lowerLimit":"15.0","upperLimit":"85.0","value":"50.0"},{"groupId":"OG016","lowerLimit":"12.1","upperLimit":"64.6","value":"33.3"},{"groupId":"OG017","lowerLimit":"0.0","upperLimit":"14.3","value":"0"},{"groupId":"OG018","lowerLimit":"16.7","upperLimit":"47.9","value":"30.0"},{"groupId":"OG019","lowerLimit":"18.1","upperLimit":"56.7","value":"35.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"7"},{"groupId":"OG014","value":"13"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"9"},{"groupId":"OG017","value":"23"},{"groupId":"OG018","value":"30"},{"groupId":"OG019","value":"20"}],"units":"Participants"}],"description":"CRR: percentage of participants with complete response (sCR or CR). sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow aspirates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory advanced multiple myeloma (MM) received PF-06863135 at a dose of 0.1 microgram/kilogram (mcg/kg) as an intravenous (IV) infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 1: PF-06863135 0.1 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 0.3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG001","title":"Part 1: PF-06863135 0.3 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG002","title":"Part 1: PF-06863135 1 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG003","title":"Part 1: PF-06863135 3 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 10 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG004","title":"Part 1: PF-06863135 10 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 30 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG005","title":"Part 1: PF-06863135 30 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 50 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG006","title":"Part 1: PF-06863135 50 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 80 mcg/kg as a subcutaneous (SC) injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG007","title":"Part 1: PF-06863135 80 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 130 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG008","title":"Part 1: PF-06863135 130 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 215 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG009","title":"Part 1: PF-06863135 215 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 360 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG010","title":"Part 1: PF-06863135 360 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 600 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG011","title":"Part 1: PF-06863135 600 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1000 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG012","title":"Part 1: PF-06863135 1000 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection every week (Q1W) on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG013","title":"Part 1.1: PF-06863135 Priming Cohort Q1W SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection every 2 weeks (Q2W) on Day 1 and 15 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG014","title":"Part 1.1: PF-06863135 Priming Cohort Q2W SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with lenalidomide at dose of 15 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG015","title":"Part 1C: PF-06863135 + Lenalidomide SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with pomalidomide at dose of 4 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG016","title":"Part 1D: PF-06863135 + Pomalidomide SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 as an IV infusion (any dose) for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG017","title":"Part 1: PF-06863135 Total IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 as a SC injection (any dose) on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG018","title":"Part 1: PF-06863135 Total SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection Q1W on Day 1, 8 ,15 and 22 of each 28-day cycle or Q2W on Day 1 and 15 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG019","title":"Part 1.1: PF-06863135 Total SC"}],"paramType":"NUMBER","populationDescription":"mITT analysis set included all participants who have received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or new anti-cancer therapies or death, whichever occurred first (maximum up to 63.31 months)","title":"Part 1: Complete Response Rate (CRR) as Per IMWG Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}